76 results about "Vitro diagnostics" patented technology

The invention discloses a reaction cup arranging device and a cup arranging control method. The cup arranging device comprises a material groove, a conveying belt, a cup fishing mechanism, a cup hitting mechanism, a vertical cache channel, a cup placing mechanism, a rotary cache mechanism and a control module. According to the cup arranging control method, a first part state machine and a second part state machine are included, the first part state machine is used for converting reaction cups in an unordered state into reaction cups in an ordered state to be output, and the second part state machine is used for outputting the reaction cups in the ordered state to other devices. According to the cup arranging device and the cup arranging control method, the reaction cups can be continuously, timely and efficiently supplemented, the operation performance and the automation level of in-vitro diagnosis equipment can be remarkably improved, and the problems that in an existing cup arranging system, the reaction cups are not supplemented in time, operation is not synchronous, and fault processing is complex are solved; and the operation efficiency of the equipment and the detection continuity are improved.

The application discloses a kind of integrated robot latex particle automatic ultrasonic dispersion equipment, including rack, quick-change head device, workpiece fixture rack, ultrasonic water bath and robot;Workpiece fixture rack is equipped with transfer clamp and placement slot, and the movable end of robot is equipped with clamp joint;Robot can drive clamp joint to butt joint or release quick-change head device, and drive quick-change head device to carry out secondary pressing positioning to sample bottle in placement slot;Robot can drive clamp joint to butt joint or release the transfer clamp of workpiece fixture rack, and robot can drive workpiece fixture rack and sample bottle thereon to carry out multidimensional composite motion in ultrasonic water bath.The equipment can realize the semi-automatic linkage operation of "feeding-positioning-ultrasonic dispersion-discharging", reduce manual intervention, guarantee the stability and consistency of latex particle dispersion in sample bottle in large-scale mass production process, significantly improve production efficiency and product quality, and provide key technical support for process upgrading of in-vitro diagnosis industry.

The present application relates to the technical field of in vitro diagnosis, in particular to antibodies of new bunyavirus and application thereof. The present application provides antibodies of new bunyavirus and application thereof. The antibodies of new bunyavirus screened by the present application can specifically bind to new bunyavirus of different mutation types, have high sensitivity and strong specificity, and have good market application prospect. The detection sensitivity of SFTSV is determined by using a double-antibody sandwich method, and the results show that the antibodies of new bunyavirus provided by the present application have a detection sensitivity as low as 0.5 ng / mL, and can be used for early diagnosis and detection of SFTSV.

The invention belongs to the technical field of biomedical detection, and discloses a TAR DNA binding protein 43 detection method based on LC-MS / MS and application. The detection method comprises the following steps: taking a biological matrix to be detected, and filtering to obtain filtrate; adding an ion enhancer into the obtained filtrate, oscillating and incubating, adding a protein precipitant, and separating precipitated protein; adding trypsin into the precipitated protein, and incubating to obtain a sample containing a characteristic peptide fragment; and detecting the TAR DNA binding protein 43 in the sample by adopting liquid chromatography-triple quadrupole mass spectrometry. According to the method, the TDP-43 is specifically detected and quantified by adopting a liquid chromatography-tandem mass spectrometry technology, so that the excellent effects of efficiently detecting and accurately quantifying the TDP-43 and improving the detection sensitivity and stability are achieved. The method can be applied to the fields of in-vitro diagnosis of neurodegenerative diseases, pathological mechanism research and therapeutic drug development.

The present application relates to the field of biotechnology and in vitro diagnosis, and relates to a monoclonal antibody of eosinophil peroxidase and application thereof. The antibody of the present application is mainly used for detecting the content of eosinophil peroxidase by western blot. The monoclonal antibody of eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody of eosinophil peroxidase specifically recognizes the linear epitope of eosinophil peroxidase.

The invention provides a photometric device for a chemiluminescence instrument, and belongs to the technical field of in-vitro diagnosis. The device comprises a mounting base, a light shading unit is fixedly mounted on the mounting base, a light metering piece is fixedly connected to the light shading unit through a light metering fixing piece, a supporting plate is fixedly mounted on the mounting base, a light metering counter is fixedly mounted on the supporting plate, and a light shading piece controlled by a transmission mechanism is slidably mounted in the light shading unit. A cup placing hole is formed in the shading piece, and a reaction cup is placed in the cup placing hole. According to the scheme, the received photon signals are converted into the electric signals through the photometric piece and transmitted to the photometric counter, the photometric counter carries out quantization processing on the electric signals, precise detection of the luminous intensity is achieved, through the design of the integrated cassette, light leakage and signal loss are reduced, the detection sensitivity and the data accuracy are remarkably improved, and the detection accuracy is improved. Meanwhile, the structural layout is simplified, and a foundation is laid for device miniaturization.

The present application relates to a kind of donor reagent in the preparation for the use of kit for the method for diagnosing whether subject is suffered from myocardial injury in vitro, wherein the method comprises: the body fluid from subject is contacted with acceptor reagent and donor reagent, and generates to be measured mixture after reaction;The intensity of signal of chemiluminescence thus produced is detected by exciting the to-be-measured mixture at least once with excitation light;The concentration of at least one myocardial marker in the body fluid is quantitatively calculated according to the intensity of signal of chemiluminescence, to determine whether subject is suffered from myocardial injury;Wherein, the donor reagent includes donor particles capable of generating active oxygen in excited state, and the particle size distribution of the donor particles in the donor reagent presents polydispersity;The surface of the first carrier is not coated or connected with polysaccharide substance, and is directly chemically bonded with one of specific binding pairing members.The method has both ultra-high sensitivity and very wide detection range.

The present invention provides a method for the diagnosis in vitro of colon cancer in a subject that comprises (i) determining in a sample isolated from the subject the expression level of at least one gene selected from the list consisting of LNC-TBP-2, CCL5, DENND2B, LRRC52-AS1, and RNF31, (ii) calculating a variable S, wherein S= A +B + C – D – E, and wherein: A is the expression level of gene LNC-TBP-2 when the expression level of gene LNC-TBP-2 is determined in step (i), or is 0 when the expression level of gene LNC-TBP-2 is not determined in step (i); B is the expression level of gene CCL5 when the expression level of gene CCL5 is determined in step (i), or is 0 when the expression level of gene CCL5 is not determined in step (i); C is the expression level of gene DENND2B when the expression level of gene DENND2B is determined in step (i), or is 0 when the expression level of gene DENND2B is not determined in step (i); D is the expression level of gene LRRC52-AS1 when the expression level of gene LRRC52-AS1 is determined in step (i), or 0 when the expression level of gene LRRC52-AS1 is not determined in step (i); and E is the expression level of gene RNF31 when the expression level of gene RNF31 is determined in step (i), or is 0 when the expression level of gene RNF31 is not determined in step (i); and (iii) diagnosing the subject as having colon cancer if S calculated in step (ii) is equal or lower than a corresponding reference value. The present invention also provides the use of LNC-TBP-2, CCL5, DENND2B, LRRC52-AS1, and RNF31 as biomarkers of CRC.

The invention relates to the technical field of in-vitro diagnosis, and particularly discloses a recyclable cleaning fluid supply system and method. Comprising a second cleaning liquid barrel storing second cleaning liquid and provided with a first pipeline, a first three-way valve connected with the first pipeline, a second three-way valve, a third three-way valve, a plunger pump located between the second three-way valve and the third three-way valve and connected with the second three-way valve and the third three-way valve, and a two-way valve connected with the third three-way valve. The needle washing pool is connected with the two-way valve; the top of a pump head in the plunger pump is connected with a third three-way valve, and the bottom of the pump head in the plunger pump is connected with a second three-way valve. A connecting pipeline among the liquid inlet end of the needle washing pool, the two-way valve, the three-way valve III and the plunger pump forms a second cleaning liquid flow path; the second cleaning solution is an alkaline or acidic cleaning solution. Recycling and cleaning maintenance of the second cleaning liquid can be achieved, the inspection cost of the analytical instrument is reduced, and meanwhile the workload of instrument operators is reduced.

The present application belongs to the pathological diagnosis technical field in vitro diagnosis, technical field, automatic dyeing, automatic sealing is integrated into a whole automatic immunohistochemical dye sealing integrated machine. The automatic immunohistochemical dye sealing integrated machine is used for dyeing and sealing treatment of the glass slide with tissue, comprising a shell, a rack, a dyeing device, a sealing device, a sample loading device, a transfer device and a control device, the dyeing device, the sealing device, the sample loading device and the transfer device are all arranged on the rack and are all electrically connected with the control device, covered by the shell, the dyeing device, the sealing device and the sample loading device are arranged in different regions, the transfer device is movably arranged above the dyeing device, the sealing device and the sample loading device, the dyeing device comprises a dyeing module and a reagent module, and the sealing device comprises a sealing module and a slide cleaning module.

There is provided a particle for the immunoagglutination assay that is a particle for immunoagglutination assay, which includes a diamond particle and a ligand that specifically binds to a biological substance. The ligand is immobilized to the diamond particle, and the particle for the immunoagglutination assay has a particle size of 50 nm or more and 1,000 nm or less.

The invention relates to the technical field of precious metal composite materials, and discloses a composite material with a core-shell structure nanometer material loaded with precious metal nanometer enzyme and a preparation method and application thereof.The preparation method of the material comprises the steps that Au NPs is prepared, specifically, pure water is kept at 100 DEG C for backflow, chloroauric acid is added, sodium citrate is added after boiling is conducted again, and after the reaction is completed, Au NPs is obtained; cooling, centrifuging, washing and resuspending; au NPs modification: dispersing Au NPs in a stabilizer solution, stirring for reaction, centrifugally washing, and resuspending; the preparation method comprises the following steps: adding ammonia water into an Au-coated SiO2: Au ethanol solution, adding TEOS (Tetraethyl Orthosilicate) in a water bath at 30 DEG C for reaction, centrifugally washing, and Preparing Au-coated SiO2-COOH: adjusting the pH value of the Au-coated SiO2 solution, then adding a carboxyl ethyl silanetriol sodium salt solution for reaction, and carrying out centrifugal washing to obtain Au-coated SiO2-COOH; the preparation method comprises the following steps: preparing Au-coated SiO2-COOH-coated NMN: carrying out ultrasonic treatment on Au-coated SiO2-COOH dispersion liquid, adding a noble metal precursor solution, carrying out ice-water bath, adding NaBH4, carrying out a reaction, carrying out centrifugal washing, and re-suspending in pure water to obtain the Au-coated SiO2-COOH-coated NMN. The composite material disclosed by the invention has good chemical stability and good biocompatibility in a complex environment, and can lay a foundation for application in the fields of in-vitro diagnosis, biological catalysis and the like.

The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer and application of the metabolic marker combination, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer. The metabolic marker combination comprises L-glucan and aspartic acid, the metabolism marker comprises a blood metabolism marker or a urine metabolism marker. The diagnosis model for distinguishing healthy individuals and kidney cancer patients is constructed by adopting L-glucan and aspartic acid, so that the diagnosis efficiency is high, and the clinical diagnosis significance is realized. In addition, 12 metabolic markers, 10 metabolic markers, 8 metabolic markers, 6 metabolic markers and 4 metabolic markers containing L-glucan and aspartic acid are respectively subjected to construction of diagnosis models for distinguishing healthy individuals from kidney cancer patients, and the constructed diagnosis models have relatively high diagnosis efficiency; the clinical diagnosis significance is realized.

Determining the modification status of nucleotide residues in a polynucleotide sample comprises (i) using a methyltransferase enzyme to apply a tag to each unmodified nucleotide residue; (ii) inactivating the methyltransferase; (iii) preparing the polynucleotide sample into a sequencing library; (iv) binding an affinity label to each tag; (v) fractionating the sequencing library into first and second fractions, wherein the first fraction is enriched for polynucleotides comprising an affinity label, and wherein the second fraction is enriched for polynucleotides lacking an affinity label; and (vi) sequencing the polynucleotides of the first and / or second fraction. Preferably, the reaction is performed in “one pot”, preferably a methyltransferase cofactor analogue is ETA AdoHcy-N3 is used alongside methyltransferase comprising a variant or fragment of the wild type M.MpeI sequence. Preferably, preparation of the polynucleotide into a sequencing library comprises end repair, A-tailing, and adapter ligation of the polynucleotides in the sample. In use, the method may be utilised for in vitro diagnosis by analysing cfDNA. A requisite kit is disclosed.

The invention provides a monoclonal antibody aiming at schistosoma japonicum SPRM1hc protein and application of the monoclonal antibody, and belongs to the technical fields of parasite infection treatment, biological medicine, immunotherapy and in-vitro diagnosis. The invention provides two monoclonal antibodies A028 and A032 which can be specifically combined with the extracellular domain of SPRM1hc protein, the actual effect of the monoclonal antibodies A028 and A032 in treatment of schistosoma japonicum katsurada after infection is verified, and the monoclonal antibodies A028 and A032 have a remarkable treatment effect in an infected animal model, and can reduce polypide load, reduce egg deposition and improve tissue pathological damage. The application of the monoclonal antibody to preparation of drugs for resisting schistosoma japonicum katsurada infection and development of schistosoma japonicum katsurada antigen detection kits has very important practical significance.

The invention discloses a biomarker for coronary heart disease diagnosis and / or severity evaluation and application thereof, and relates to the technical field of biomedical detection and in-vitro diagnosis. The biomarker is at least one of a complement C1r and a complement C8, and the invention further provides application of a detection reagent of the biomarker in preparation of products for coronary heart disease diagnosis and / or coronary heart disease severity evaluation, coronary heart disease early screening and coronary heart disease prognosis evaluation. The invention also provides a kit for diagnosing the coronary heart disease and / or evaluating the severity of the coronary heart disease. The complement C1r and the complement C8 can be used as biomarkers for diagnosing the coronary heart disease and evaluating the severity of the coronary heart disease, and the research blank of the complement system in the field of evaluation of the severity of the coronary heart disease is filled. The detection method is based on a blood sample, invasive operation is not needed, the patient risk and the detection cost are reduced, and the method is suitable for clinical large-scale screening and long-term dynamic monitoring.

The invention relates to an antigen construct for rapid immune detection, in particular to an antigen molecule for realizing dimerization or trimerization through foldon or a variant thereof. The antigen construct can enhance the conformation stability and improve the antibody binding efficiency, so that the sensitivity and shelf life stability in colloidal gold, fluorescent microspheres, ELISA (enzyme-linked immuno sorbent assay) and other in-vitro diagnosis methods in immunochromatography are remarkably improved. The construct is suitable for antibody detection of rabies, influenza, coronavirus, Brucella, tuberculosis and the like in zoonosis and HIV, HBV, HCV, syphilis and the like in human infectious diseases, and can be widely applied to clinical screening, animal quarantine, family self-test and public health emergency monitoring.

1. The name of the design product: nucleic acid amplification detection analyzer. 2. The use of the design product: the design product is a nucleic acid amplification detection analyzer, which is used for in vitro diagnosis of nucleic acid amplification detection analysis. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The present application relates to the technical field of in vitro diagnosis protein marker, in particular to a preservative for horseradish peroxidase marker and application thereof. The present application provides a preservative for horseradish peroxidase marker and application thereof. The preservative comprises lecithin 0.05-1.0 g / L, bovine serum albumin 2-10 g / L, sodium chloride 5-30 g / L, polyaspartic acid 2-10 g / L, and the rest is glycerol. The preservative can significantly improve the storage stability of enzyme-labeled product, and the activity of enzyme-labeled antibody can still maintain more than 70% after 21 days of storage at 37 DEG C. In the bottle opening stability test, the activity of enzyme-labeled antibody can maintain more than 87% after 45 days of storage at 4 DEG C.

The present invention relates to a method of detecting and / or quantifying the presence of exons 5 and 6 of ANRIL (Antisense Noncoding RNA in the INK4 Locus) in a subject, comprising the following steps of: 1) Preparation of total RNA from a biological sample of the subject, 2) Conversion of RNA molecules into complementary DNA, 3) Loop-mediated isothermal amplification using trans-exonic oligonucleotides that specifically amplify exons 5 and 6, 4) Addition of Cas12a / RNA guides complexes, wherein RNA guide specifically targets exons 5 and 6 by base pairing, 5) Addition of a reporter DNA probe, 6) Detection of cleavage products, wherein detection of cleavage products reveals the presence of exons 5 and 6 of ANRIL, and 7) possibly quantifying expression of exons 5 and 6 of ANRIL. The present invention also relates to a method for in vitro diagnosis of a cancer in a subject, to a method for in vitro prognosis a cancer in a subject to a kit for implementing the method and to a set of oligonucleotides.

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.

The invention provides application of aldosterone in diagnosis of amyotrophic lateral sclerosis, and particularly provides application of a reagent for detecting the aldosterone level in a sample in preparation of products for in-vitro diagnosis, auxiliary diagnosis and / or illness monitoring of amyotrophic lateral sclerosis. By simply detecting the aldosterone level in a serum sample, accurate diagnosis and illness monitoring of ALS can be realized.

The present invention generally relates to the use of metabolic biomarkers for the diagnosis of endometriosis, and more specifically to an ex vivo method for diagnosing endometriosis in a subject. The present invention further relates to a system and kit for diagnosing endometriosis.

The invention discloses an anti-cat IgE (Immunoglobulin E) monoclonal antibody hybridoma cell strain, a monoclonal antibody and application of the monoclonal antibody, and belongs to the fields of immunology, in-vitro diagnosis and detection technologies and hybridoma antibody preparation. A cat IgE antigen is purified through a salting-out method and column chromatography, after mice are immunized, 6B5 and 13E11 hybridoma cell strains are screened out through cell fusion, IgG type antibodies secreted by the hybridoma cells do not have cross reaction with cat IgG, EC50 values are smaller than or equal to 0.0261 and 0.0274 respectively, the titer is larger than or equal to 1: 100000, and the purity is larger than or equal to 95%. According to the present invention, the 6B5 and 13E11 antibody combination is used for colloidal gold chromatography detection, the distance between the detection line and the quality control line is optimized to 0.5 cm, the double-antibody sandwich system is constructed, the detection sensitivity reaches 0.1 ng / mL, and 8 clinical allergic cat samples are completely positive through verification; the invention breaks through the bottleneck of the traditional detection technology, provides a high-specificity and high-sensitivity cat IgE detection scheme, lays a foundation for early diagnosis and precise medical treatment of cat allergic diseases, and has remarkable clinical application value and industrial prospect.

The present application relates to a tumor risk prediction method and device based on cfDNA nucleosome fingerprint, belonging to the technical field of in vitro diagnosis. Among them, the method comprises: obtaining whole genome sequencing data of plasma or serum cfDNA; the whole genome sequencing data is subjected to quality control processing to remove non-human sequences to obtain human cfDNA sequencing fragments; the human cfDNA sequencing fragments are aligned to the human reference genome to obtain the genomic coordinates of each fragment and the coverage information thereof on the reference genome; based on the whole genome coverage signal, the enrichment region identification algorithm is used to determine the nucleosome positioning boundary, and the peak signal strength is taken as the nucleosome positioning intensity score; the nucleosome positioning intensity score is input into the tumor risk prediction model which has been trained, and the prediction risk probability of the subject suffering from tumor is output. Greatly improve the accuracy of noninvasive screening tumor prediction tumor risk, and the detection cost is low and the cycle is short.

The invention discloses a bigeminy immunoassay kit for detecting an HPV (human papillomavirus) antibody and a preparation method of the bigeminy immunoassay kit, relates to the field of biomedicine, and is characterized in that the bigeminy immunoassay kit for detecting the HPV antibody and the preparation method of the bigeminy immunoassay kit are provided. The magnetic microspheres for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 are coated with an HPV16 antibody and an HPV18 antigen, acridinium ester is used for marking the HPV16 antigen and the HPV18 antibody, an in-vitro diagnostic kit for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 is established on the basis, and a chemiluminescence immunoassay method is combined for analysis. The bigeminy immunoassay kit for quantitative detection of the HPV antibody is high in sensitivity, good in specificity, simple and convenient to operate and appropriate in price.

The invention belongs to the technical field of molecular biology and in-vitro diagnosis, and particularly discloses an LAMP (loop-mediated isothermal amplification) primer probe composition for detecting folic acid MTHFR (methylenetetrahydrofolate reductase) gene polymorphism, a kit and application of the LAMP primer probe composition. A probe-mediated LAMP melting curve analysis system is constructed, efficient nucleic acid amplification is realized under a constant-temperature condition by utilizing LAMP reaction, and rapid and accurate typing of C677T mutation sites is realized by combining high-specificity discrimination characteristics of a double-labeled probe melting curve. Compared with a traditional method, the method has the advantages of being short in reaction time, high in sensitivity, high in specificity, free of complex instruments and follow-up operation and the like, and is suitable for clinical rapid typing detection and basic molecular diagnosis application.